Placebo for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Sep 2025: Trial registered, NCT07174310
  2. 24 Nov 2025: Trial started, NCT07174310

The trials

NCT07174310: A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

State
Under way
Phase
Phase 3
People
900 planned
Started
24 Nov 2025
Primary completion
30 Jun 2029
Arms
Placebo
Results
None posted
Papers
doi:10.1016/s0140-6736(26)00865-2
  1. 15 Sep 2025: Trial registered
  2. 24 Nov 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.